Compare Natera Inc. Common Stock (NTRA) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares UltraPro Short QQQ ETF — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while ProShares UltraPro Short QQQ ETF trades at $37.3 (market cap $2.13B). The key difference: Natera Inc. Common Stock is far larger — about 26.8× ProShares UltraPro Short QQQ ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| NTRA | SQQQ | |
|---|---|---|
Market Cap | $57.03B | $2.13B |
Volume | 1,131,157 | 57,212,015 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $89.43 |
52-Week Low | $179.42 | $31.83 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $33.98, up 1.04% today. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, it aims to deliver triple the daily inverse performance of the Nasdaq-100 Index. Recent news highlights its use as a hedging tool against tech sector declines, with articles noting potential benefits if the AI-fueled tech rally weakens.
The outlook for SQQQ is inherently tied to Nasdaq-100 volatility; it offers strategic hedging opportunities during market downturns but carries high risk due to leverage decay and daily rebalancing. Investors face significant loss potential if the tech rally persists, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
